A 12 day placebo- and reference-controlled, double-blind, single center, randomized, phase II clinical study with an intraindividual comparison, investigating the anti-psoriatic efficacy and the tolerability of LAS41002 lotion in a psoriasis plaque test

Registry ID

EUCTR2009-016629-33

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

Almirall Hermal GmbH

Start date

2009-12-16

Completion date

2010-03-05

Last update

2026-08-16

Conditions

• Psoriasis vulgaris

Summary

The primary objective of this study is the clinical examination (visually and by palpating the respective test area) of the reduction of psoriatic lesions: LAS41002 lotion better than (superior to) placebo at study day 12.

Locations

• , , Germany

Related clinical trials

• Investigation of maintaining factors of depressive disorders in patients with psoriasis
• Evaluation of a structured, guideline-based, multimodal care model for people with inflammatory skin diseases
• Pharmacological conditioning as a drug dose reduction strategy in patients with psoriasis
• Characterising inflammatory and malignant skin diseases
• Pruritus and Psoriasis - experimental analyses of itch in patients with psoriasis
• Disease trajectories in Atopic Dermatitis and Psoriasis

View on source registry